Kwan Goo Edmond (Ed) Cho, an industry veteran with experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea.
As president, Cho will have full profit and loss responsibility and overall accountability for all aspects of the Harlan Contract Research Services (CRS) business stream serving the Korean chemical, agrochemical, and pharmaceutical markets.
Prior to joining Harlan CRS, Cho was director of market access and business development for Zuellig Pharma Korea, an $8 billion subsidiary of the Zuellig Group, providing contract services and clinical reach to multinational companies in more than 15 countries. He also held sales, marketing, and management positions during his 14 years with LG Life Sciences and served in the Special Forces of the Korean Army.
Cho earned a bachelor’s degree and Doctor of Veterinary Medicine degree from Seoul National University.